Literature DB >> 15206053

Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City.

Patricia A Bradford1, Simona Bratu, Carl Urban, Melissa Visalli, Noriel Mariano, David Landman, James J Rahal, Steven Brooks, Sanda Cebular, John Quale.   

Abstract

Nineteen isolates of carbapenem-resistant Klebsiella species were recovered from 7 hospitals in New York City. Most K. pneumoniae belonged to a single ribotype. Nucleotide sequencing identified KPC-2, a carbapenem-hydrolyzing beta -lactamase. In 3 strains, TEM-30, an inhibitor-resistant beta -lactamase, was detected. Carbapenem-resistant Klebsiella species possessing KPC-2 are endemic in New York City. This study documents the identification of an inhibitor-resistant TEM beta -lactamase in the United States.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15206053     DOI： 10.1086/421495

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  179 in total

1.  Rectal screening for Klebsiella pneumoniae carbapenemases: comparison of real-time PCR and culture using two selective screening agar plates.

Authors:  Kamaljit Singh; Kathy A Mangold; Kody Wyant; Donna M Schora; Barbara Voss; Karen L Kaul; Mary K Hayden; Vishnu Chundi; Lance R Peterson
Journal:  J Clin Microbiol       Date:  2012-05-23       Impact factor: 5.948

2.  A pilot survey of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae mediated by K pneumoniae serine carbapenemases in a regional referral hospital in British Columbia.

Authors:  Aubrey Shannon; Ken Wagner; Naowarat Cheeptham; Gwen Stephens
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

3.  Role of ISKpn7 and deletions in blaKPC gene expression.

Authors:  Thierry Naas; Gaelle Cuzon; Ha-Vy Truong; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

4.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

5.  Characterization of a novel Klebsiella pneumoniae sequence type 476 carrying both bla KPC-2 and bla IMP-4.

Authors:  Y Wang; W Cao; X Zhu; Z Chen; L Li; B Zhang; B Wang; L Tian; F Wang; C Liu; Z Sun
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-21       Impact factor: 3.267

6.  First Canadian outbreak of Enterobacteriaceae-expressing Klebsiella pneumoniae carbapenemase type 3.

Authors:  Victor Leung; Vivian G Loo; Charles Frenette; Marc-Christian Domingo; Anne-Marie Bourgault; Michael R Mulvey; Hugh G Robson
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

Review 7.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients.

Authors:  Alessandro Russo; Simone Giuliano; Giancarlo Ceccarelli; Francesco Alessandri; Alessandra Giordano; Grazia Brunetti; Mario Venditti
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 9.  Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae.

Authors:  Agnese Lupo; Krisztina M Papp-Wallace; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal:  Diagn Microbiol Infect Dis       Date:  2013-10-03       Impact factor: 2.803

10.  KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.

Authors:  Mao Hagihara; Jared L Crandon; Carl M Urban; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.